

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

**Marstacimab for treating severe haemophilia A or severe
haemophilia B in people 12 years and over [ID6342]**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Stakeholders at scoping raised concerns that females who carry the haemophilia gene and females with severe haemophilia A or severe haemophilia B should not be excluded from accessing the technology. The NICE technical team also note that some of the treatments for haemophilia A and B are derived from human blood or human or animal cells. This may not be considered acceptable by people with some religious beliefs.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee?

The remit and population have been kept broad, to include all people with severe haemophilia A or severe haemophilia B regardless of biological sex or gender. Where relevant, the committee should consider whether there is the potential for inequity of access based on biological sex or gender in making its recommendations.

If appropriate the committee may consider the treatment options available for people who cannot have blood or animal products during guidance development.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

The remit and population have been kept broad and includes all people with severe haemophilia A and B. Any relevant equalities considerations should be explored by the committee.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

None. The stakeholder group 'Hospital Information Services - Jehovah's Witnesses' is included on the stakeholder list.

Approved by Associate Director (name): Ian Watson

Date: 15/05/2024